Endomyocardial Fibrosis Treatment & Management
- Author: Ali A Sovari, MD, FACP; Chief Editor: Henry H Ooi, MD, MRCPI more...
In general, the response to medical therapy is unproven due to lack of well-designed studies.
Because most patients with endomyocardial fibrosis (EMF) present long after any possible period of early active myocarditis may have existed, little, if any, role exists for immunosuppressive therapy as is used in some patients with Löeffler disease. If the patient presents with acute myocarditis, prednisone may be considered as medical therapy.
Symptomatic therapy with diuretics has been shown to be useful. Similar to other patients with diastolic dysfunction, these patients may also benefit from ACE inhibitors, angiotensin receptor blockers, and beta-blockers, but only to some degree.
For patients with severe symptoms, consider surgical therapy because the prognosis for these patients with continued medical therapy alone is dismal.
There is no reliable evidence on the rate of the embolic events in these patients and whether anticoagulation and antiplatelet therapy are effective in their prevention. It is reasonable to anticoagulate patients who have thrombus on echocardiography and are compliant with medical treatments. Antiplatelet therapy with aspirin or clopidogrel can be considered as an alternative approach. Those patients with atrial fibrillation should be anticoagulated, although the ability to do this safely and effectively is again limited by availability of local services in endemic regions.
Surgical therapy by endocardial decortication seems to be beneficial for many patients with advanced disease who are in functional-therapeutic class III or IV. The operative mortality rate is high (15-20%), but successful surgery has a clear benefit on symptoms and seems to favorably affect survival as well.
The most commonly used approach is endocardiectomy, combined with mitral and/or tricuspid repair or replacement (when indicated), using a midline thoracotomy and cardiopulmonary bypass. Depending on the location of the disease (right or left ventricle, apex or inflow tract), a transapical or transventricular approach can be used.
Because a well-defined plane of cleavage usually exists between the endocardium and myocardium, endocardiectomy is most frequently feasible. Because the myocardium is not usually affected, the severe hemodynamic derangement associated with EMF is relieved with successful resection of the endocardium. Common postoperative complications include low cardiac output, heart block, and ventricular arrhythmias.
No specific diet is recommended for this condition.
No activity restrictions are recommended because activity restrictions have not been proven to alter the prognosis of this condition, and no specific activity has been shown to hasten the onset of fatal arrhythmias or sudden death.
Dato I. How to recognize endomyocardial fibrosis?. J Cardiovasc Med (Hagerstown). 2014 Jul 21. [Medline].
Rossi S, Baruffi S, Bertuzzi A, Miragoli M, Corradi D, Maestri R, et al. Ventricular activation is impaired in aged rat hearts. Am J Physiol Heart Circ Physiol. 2008 Dec. 295(6):H2336-47. [Medline].
Miragoli M, Salvarani N, Rohr S. Myofibroblasts induce ectopic activity in cardiac tissue. Circ Res. 2007 Oct 12. 101(8):755-8. [Medline].
Gupta PN, Valiathan MS, Balakrishnan KG, et al. Clinical course of endomyocardial fibrosis. Br Heart J. 1989 Dec. 62(6):450-4. [Medline].
Sovari AA, Morita N, Weiss JN, Karagueuzian HS. Serum transforming growth factor-beta1 as a risk stratifier of sudden cardiac death. Med Hypotheses. 2008 Aug. 71(2):262-5. [Medline].
Valiathan SM, Kartha CC. Endomyocardial fibrosis--the possible connexion with myocardial levels of magnesium and cerium. Int J Cardiol. 1990 Jul. 28(1):1-5. [Medline].
Mocumbi AO, Falase AO. Recent advances in the epidemiology, diagnosis and treatment of endomyocardial fibrosis in Africa. Heart. 2013 Oct. 99(20):1481-7. [Medline].
Mocumbi AO, Ferreira MB, Sidi D, Yacoub MH. A population study of endomyocardial fibrosis in a rural area of Mozambique. N Engl J Med. 2008 Jul 3. 359(1):43-9. [Medline].
Hassan WM, Fawzy ME, Al Helaly S, Hegazy H, Malik S. Pitfalls in diagnosis and clinical, echocardiographic, and hemodynamic findings in endomyocardial fibrosis: a 25-year experience. Chest. 2005 Dec. 128(6):3985-92. [Medline].
Rutakingirwa M, Ziegler JL, Newton R, Freers J. Poverty and eosinophilia are risk factors for endomyocardial fibrosis (EMF) in Uganda. Trop Med Int Health. 1999 Mar. 4(3):229-35. [Medline].
Barretto AC, Mady C, Oliveira SA, et al. Clinical meaning of ascites in patients with endomyocardial fibrosis. Arq Bras Cardiol. 2002 Feb. 78(2):196-9. [Medline].
Iles L, Pfluger H, Phrommintikul A, et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol. 2008 Nov 4. 52(19):1574-80. [Medline].